A Study Lasmiditan (LY573144) in a Single Migraine Attack in Japanese Participants With Migraine

PHASE2CompletedINTERVENTIONAL
Enrollment

846

Participants

Timeline

Start Date

May 31, 2019

Primary Completion Date

June 8, 2020

Study Completion Date

June 8, 2020

Conditions
Migraine
Interventions
DRUG

Lasmiditan

Administered orally

DRUG

Placebo

Administered orally

Trial Locations (34)

5560017

Tominaga Hospital, Osaka

9300803

Sakura Clinic Internal Medicine Neurology, Toyama

790-0925

Takanoko Hospital, Matsuyama

816 0824

Ikeda Neurosurgical Clinic, Kasuga-shi

816-0802

Jinnouchi Neurosurgery Clinic, Kasuga-shi

373-8585

SUBARU Health Insurance Society Ota Memorial Hospital, Ota-shi

060 8570

Nakamura Memorial Hospital, Sapporo

658-0064

Kohnan Hospital, Kobe

663-8014

Nishinomiya Municipal Central Hospital, Nishinomiya

663-8204

Yamaguchi Clinic, Nishinomiya-shi

211-8588

Fujitsu Clinic, Kawasaki

982-0014

Sendai Headache and Neurology Clinic, Sendai

700-8557

Okayama City General Medical Center Okayama City Hospital, Okayama

555-0034

Chibune General Hospital, Osaka

560-0012

Takase internal medicine clinic, Toyonaka-shi

840-0806

Osoegawa Neurology Clinic, Saga

350-0495

Saitama Medical University Hospital, Iruma-Gun

338-8577

Saitama Neuropsychiatric Institute, Saitama

359-1141

Saino Clinic, Tokorozawa

321 0293

Dokkyo Medical University Hospital, Shimotsuga-Gun

182-0006

Niwa Family Clinic, Chofu-shi

108-0075

Sanno Clinic Shinagawa, Minato-ku

156-0043

USUDA CLINIC for internal medicine, Setagaya-ku

151-0051

Tokyo Headache Clinic, Shibuya-ku

160-0017

Fukuuchi Pain Clinic, Shinjuku-ku

400-0124

Nagaseki Headache Clinic, Kai-Shi

730-0031

Doi Clinic Internal Medicine Neurology, Hiroshima

892-0844

Tanaka neurosurgical clinic, Kagoshima

780-8011

Umenotsuji Clinic, Kochi

862-8505

Kumamoto City Hospital, Kumamoto

600-8811

Tatsuoka Neurology Clinic, Kyoto

606-0851

Ishikawa Clinic, Kyoto

530-0012

Osaka Saiseikai Nakatsu Hospital, Osaka

420-0853

Japanese Red Cross Shizuoka Hospital, Shizuoka

All Listed Sponsors
lead

Eli Lilly and Company

INDUSTRY

NCT03962738 - A Study Lasmiditan (LY573144) in a Single Migraine Attack in Japanese Participants With Migraine | Biotech Hunter | Biotech Hunter